We describe lead compound MIDD0301 for the oral treatment of asthma based on previously developed positive allosteric α5β3γ2 selective GABAA receptor (GABAAR) modulators. MIDD0301 relaxed airway smooth muscle at single micromolar concentrations as demonstrated with ex vivo guinea pig tracheal rings. MIDD0301 also attenuated airway hyperresponsiveness (AHR) in an ovalbumin murine model of asthma by oral administration. Reduced numbers of eosinophils and macrophages were observed in mouse broncho-alveolar lavage fluid without changing mucous metaplasia. Importantly, lung cytokine expression of IL-17A, IL-4, and TNF-α were reduced for MIDD0301 treated mice without changing anti-inflammatory cytokine IL-10 levels. Automated patch clamp confirmed amplification of GABA induced current mediated by α1-3,5β3γ2 GABAARs in the presence of MIDD0301. Pharmacodynamically, transmembrane currents of ex vivo CD4 + T cells from asthmatic mice were modulated by MIDD0301 in the presence of GABA. The number of CD4 + T cell observed in the lung of MIDD0301 treated mice were reduced by an oral treatment of 20 mg/kg b.i.d. for 5 days. A half-life of almost 14 hours was demonstrated by pharmacokinetic studies (PK) with no adverse CNS effects when treated mice
INTRODUCTION
Asthma is characterized by chronic inflammation of the airways resulting in hyperactivity to external stimuli and airway obstruction. 1 Common clinical features include recurrence or episodes of cough, chest tightness, shortness of breath, and wheezing. Asthma is a major global health concern, estimated at 300 million people affected worldwide, with 21 million in the United States alone. Global asthma prevalence is estimated to reach 400 million in year 2025. 2, 3 Despite the growing challenge of asthma, currently approved therapeutic options are limited.
The preferred therapy for chronic persistent asthma includes inhaled corticosteroids and inhaled long acting β2 adrenergic receptor agonists (LABAs). 4 Aerosol administration allows for targeted lung drug delivery, thus avoiding systemic side effects associated with these drugs.
Nevertheless, asthma morbidity and mortality continues to rise. One important factor is the failure of patients to properly use inhaled medications leading to non-compliance and loss of asthma control. 5, 6 An alternative for patients whose symptoms are poorly controlled with inhaled steroids is oral leukotriene receptor antagonists. 2 However, genetic variations in leukotriene signaling genes may preclude their widespread efficacy. 7 It has been reported that 35-78% of patients are nonresponsive to such medications. 8, 9 Finally, injectable biologics such as Omalizumab and Meolizumab were developed to reduce asthma lung inflammation, but patient costs for these drugs of up to $30,000 a year limits their use to only severe disease. 10, 11 These biologics are also unable to protect against acute bronchospasm and present anaphylaxis risks.
An improved drug for asthma would alleviate the multiple acute and chronic disease symptoms such as airway smooth muscle constriction and airway inflammation. Importantly, it should be orally active to eliminate poor aerosol compliance and have limited cardiovascular and central nervous system (CNS) adverse effects. To address these needs, our laboratory has advanced the development of a new asthma medication based on positive allosteric subtype selective GABAA receptor modulation. These compounds do not cross the blood brain barrier and target asthma pathophysiology without systemic side effects. [12] [13] [14] The GABAA receptor (GABAAR) is a ligand-gated chloride ion channel best known for its role in CNS inhibitory neurotransmission.
GABAARs are heteropentameric membrane receptors mainly consisting of combinations of 19 different subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1-3). Classical GABAARs consist of 2 alpha, 2 beta, and one "tertiary" subunit (γ, δ, ε, θ, or π). 15, 16 Importantly, discrete GABAAR subtypes have been identified in airway smooth muscle, airway epithelium, and inflammatory cells. 12, 13, [17] [18] [19] [20] [21] Their activation by positive allosteric modulators relaxed isolated pre-constricted airway smooth muscles and reduced inflammation and airway hyperresponsiveness (AHR) in murine asthma models. 12, 13, 18, 19, [21] [22] [23] [24] [25] Notably, an α5β3γ2 GABAAR selective compound 2 ( Figure 1 In addition, the number of leukocytes, especially eosinophils, in ova s/c mouse lungs were reduced with compound 2 treatment. However, the number of lung CD4 + T cells was not reduced statistically compared to vehicle-treated mice, and electrophysiological analysis showed that compound 2 modulation of GABA-induced current responses of isolated CD4 + T cells from ova s/c mice was negligible. To improve the performance of compound 2, further development produced lead compound MIDD0301 ( Figure 1 ) that reduced AHR at lower dosage, significantly limited the number of CD4 + T cells, and reduced the expression of pro-inflammatory cytokines.
EXPERIMENTAL SECTION
Chemicals. MIDD0301 was synthesized using a published procedure. 26 The purity was of >98% was confirmed by HPLC. Identity was determined by 1 H-NMR, 13 Ovalbumin sensitization and challenge. Randomized male Balb/c mice in groups of ten were sensitized three times with intraperitoneal (i.p.) injections of 2 mg/kg/d of ovalbumin (ova) (Sigma-Aldrich, St. Louis, MO) emulsified in 2 mg of alum (Imject Alum; Thermo Scientific, Pierce, Rockford, IL) on days 0, 7, and 14, in a total volume of 100 μL. Mice were anesthetized with isoflurane and challenged intranasally (i.n.) with 1 mg/kg/d ova for 5 days. 27 Control mice were sensitized with ova and challenged with i.n. saline. The effects of MIDD0301 at 20, 50 and 100 mg/kg administered 5 days during the ova challenge period were tested in separate groups of ten ova s/c Balb/c mice. As a positive control, separate groups of ova s/c BALB/c mice received salmeterol at 1 mg/kg b.i.d. for 5 days. Airway hyper-responsiveness parameters were assessed on day 28, and mice were sacrificed using an overdose of ketamine/xylazine i.p. on day 29 for assessment of inflammatory cells and mucus metaplasia.
Drug treatment protocol. Sterile solutions of MID0301 and salmeterol were prepared in 2%
hydroxypropyl methylcellulose solution (Sigma-Aldrich, St. Louis, MO) and 2.5% polyethylene glycol (Sigma-Aldrich, St. Louis, MO) in a biological safety cabinet. A fine suspension was obtained by grinding the mixture with a mortar and pestle. MIDD0301 or salmeterol were administered by oral gavage at different concentrations with 20G gavage needles (Kent Scientific Corporation, Torrington CT) to groups of ova s/c Balb/c twice daily for 5 days during the ova challenge period. Mice received a single p.o. dose of compound just before airway parameter measurements. Mice were monitored daily after drug administration.
Airway smooth muscle relaxation. Guinea pig experiments were approved by the Columbia University IACUC. Adult male Hartley guinea pigs were euthanized by intraperitoneal pentobarbital (100 mg/kg). The tracheas were surgically removed and transected into crosssections containing two cartilaginous rings. The rings were washed for one hour with at least five buffer exchanges to remove any pentobarbital. After the epithelium was removed with a cotton swab, the rings were suspended from two silk threads in a 4 mL jacketed organ bath (Radnoti Glass Technology), with one thread attached to a Grass FT03 force transducer (Grass-Telefactor) coupled to a computer via Biopac hardware and Acknowledge 7.3.3 software (Biopac Systems) for continuous digital recording of muscle tension. The rings were bathed in 4 ml of KH buffer solution (composition in mM: 118 NaCl, 5.6 KCl, 0.5 CaCl2, 0.2 MgSO4, 25 NaHCO3, 1.3 NaH2PO4, 5.6 D-glucose) with 10 μM indomethacin (DMSO vehicle final concentration of 0.01%), which was continuously bubbled with 95% O2 and 5% CO2 at pH 7.4, 37 °C. The rings were equilibrated at 1 g of isotonic tension for 1 h with new KH buffer added every 15 min. All rings were precontracted with 10 μM N-vanillylnonanamide (capsaicin analog) and then two cycles of cumulatively increasing concentrations of acetylcholine (0.1−100 μM) with extensive buffer washes between and after those two cycles with resetting of the resting tension to 1.0 g.
Tetrodotoxin (1 μM) and pyrilamine (10 μM) were added to the buffer in the baths to eliminate the confounding effects of airway nerves and histamine receptors. After a stable baseline at 1.0 g resting tension was established, tracheal rings were contracted with 1 μM of substance P. After the peak contraction was reached, indicated concentrations of MDD0301, or vehicle (0.1% DMSO) was added to the bath. The percentage of initial contraction remaining at indicated time points after compound exposure was expressed as a percentage of the remaining contractile force in vehicletreated tissues and compared between groups.
Assessment of airway hyperresponsiveness. AHR to methacholine in conscious, spontaneously breathing animals was measured by DSI's Buxco FinePointe Non-Invasive Airway Mechanics (NAM) instrument 28 . Before measurements were taken, mice were acclimated to the chambers 15 min daily for 5 days. The chambers were also calibrated each time before data collection. Briefly, the nasal chamber in combination with the thoracic chamber allows the computation of specific airway resistance (sRaw). The FinePointe software computes specific airway resistance with all other ventilatory parameters derived by the NAM analyzer. Mice were exposed to aerosolized PBS (for the baseline measurement) or methacholine (1.5625−12.5 mg/ mL) for 1 min and readings were taken and averaged for 3 min after each nebulization. Data obtained were presented as sRaw versus the methacholine concentration (mg/mL) used to generate the aerosol 12, 13 .
Drug pharmacokinetic studies, rotarod studies and patch clamp studies with transient transfected cells. (see Supporting Information)
Automated patch-clamp with CD4 + T-lymphocytes. Four BALB/c mouse spleens were isolated and excised through a strainer using the plunger of a syringe. The cells were washed through the strainer with PBS and centrifuged for 5 min at 1,600 rpm. After aspiration of the supernatant the cell pellet was resuspended in BD Pharm Lyse lysing solution (BD Biosciences, San Jose, CA), followed by incubation (2 min at 37°C), addition of 30 ml PBS and centrifugation (5 minutes at 1,600 rpm). CD4 + T cells were isolated from splenocytes using an Affymetrix eBiosciences MagniSort mouse CD4 + T cell enrichment kit following manufacturer's instructions (Thermo Fisher Scientific Inc., Rockford, IL). After isolation, cells were centrifuged at 380g for 2 min and gently suspended in extracellular solution (in mM: NaCl 140, KCl 5, CaCl2 2, MgCl2 1, glucose 5, HEPES 10, pH 7.4 with NaOH) at a concentration of 5x10 6 cells/ml. Automated patch clamp assays were conducted with the IonFlux16 as described previously. 12, 13 Briefly, the IonFlux16 Data was analyzed subsequently using Cell Quest pro software (BD Pharmingen, San Jose, CA).
Gating strategies for the different markers and treatment groups are shown in Supporting Information. The total inflammatory cell count was obtained by running all samples on high (60 μL/ min) for 180 s. The gated anti-mouse CD45 positive events in the fourth channel (FL4) were used to calculate the total inflammatory cell count as cells/mL. The frequencies of CD4 + , F4/80 + and Siglec-F + cell populations in their respective gates were multiplied by the total inflammatory cell count (cells/mL) to obtain the differential cell population. Following lung perfusion, the trachea was tied with a suture to avoid leakage of the formalin and to ensure the lungs were well fixed. The lungs were then isolated from the thoracic cavity and kept in 10% neutral buffered cold formalin for 48 hours at 4 0 C. The left lobe was then sectioned transversely into two. Lung samples were dehydrated, paraffin embedded, and sectioned. 6 μm sections were placed onto positively charged slides, dewaxed with Histoclear (National Diagnostics), and rehydrated in graded concentrations of ethanol. Following rehydration, the sections were oxidized in 1% periodic acid and incubated in fluorescent Schiff's reagent for 20 minutes at room temperature. The slides were washed with distilled water, rinsed in acidic alcohol, and cover slipped with Canada balsam and methyl salicylate mounting media to obtain counterstained slides. 29, 30 The PAFS-stained slides were examined under an EVOS fluorescence microscope and images from random fields of the lung tissue were acquired from the axial bronchi.
The image J software was used to obtain mucin volume density by morphometrically determining the area of mucin glycoprotein in the epithelium per length of the basement membrane. 29, 30 Scale bars obtained during image acquisition were used to scale the images. 
RESULTS

MIDD0301 effectively relaxes airway smooth muscle.
The GABAAR 4 and 5 subunits were identified previously in human and guinea pig airway smooth muscle. 18 Furthermore, these GABAAR can be targeted with subtype selective ligands to mediate smooth muscle relaxation. 13, 19 We assessed the smooth muscle relaxation potency of MIDD0301 in guinea pig tracheal rings ex vivo contracted with substance P. Direct action of substance P on the neurokinin 1 receptor (NK1R) can lead to a series of GPCR signaling events including Gq coupling, phospholipase C activation, formation of IP3, and DAG, with subsequent Ca 2+ mobilization. 31 A mechanism of smooth muscle contraction involving a decrease in membrane K + permeability with subsequent membrane depolarization has also been previously proposed. 32 The activity of MIDD0301 is depicted in Figure 2 . (Figure 3, B) , but with increased significance for control and treatment groups. Reducing the oral dose to 20 mg/kg reflected a downward trend for the sRaw value at 12.5 mg/ml methacholine, however, the effect did not reach statistical significance (p value of 0.507; Figure 3 , C). Furthermore, we compared MIDD0301 with LABA salmeterol using the same route and frequency of administration at 1 mg/kg ( Figure 3D ).
Interestingly, no AHR effect was observed for this approved inhaled asthma medication. In addition, a single high oral dose of salmeterol at 10 mg/kg was given acutely before the measurement without any significant effect on AHR (data not shown).
MIDD0301 is well distributed but with limited CNS exposure. The pharmacokinetic profile of MIDD0301 was investigated in mice over a period of 24 hours. The concentrations of MIDD0301
were quantified by LCMS/MS in blood, brain, and lung following a single oral administration of 25 mg/kg (Figure 4 ). Within 40 minutes (Tmax), MIDD0301 reached maximum absorption in blood and lung. The Cmax for blood was 8.24 μg/g and 4.39 μg/g for lungs. The compound was well distributed in blood and lung with an AUC of 2087.1 and 1390.5 µg*min/g, respectively. The rate of elimination for MIDD0301 in the blood was slow at 0.001 min -1 resulting in a long half-life of 836 minutes. The elimination rate of MIDD0301 was somewhat faster in lung tissue. Further in vitro microsomal stability studies revealed that MIDD0301 is significantly more stable in human (t1/2 = 1546 minutes) than in mouse (t1/2 = 549 minutes) (Supporting Information). The mouse plasma protein binding of MIDD0301 is 88% (Supporting Information). Poor blood brain barrier penetration of MIDD0301 resulted in an extremely low AUC of 107.7 µg*min/g in the brain. Although this study showed negligible brain exposure to the compound, the absence of any possible adverse CNS effects such as sedation or ataxia caused by MIDD0301 was confirmed by a rotarod study ( Figure   4 , B). Here, groups of mice were treated orally with vehicle or 100 mg/kg of MIDD0301 and evaluated on a rotating rod for periods of three minutes at three different time points. All treated mice were able to successfully stay on the rotating rod during these time periods confirming the absence of sensorimotor inhibition by MIDD0301 in contrast to brain permeable positive control diazepam.
MIDD0301 is acting through the GABAAR. Immune cells express multiple GABAAR subunits
and react electrophysically when exposed to GABA and GABAAR ligands. [22] [23] [24] Recently we showed that α4β3γ2, and to a lesser extent α5β3γ2, subtype selective GABAAR ligands increase the current response of T lymphocytes in the presence of GABA. 12, 13 Accordingly, we investigated the dose dependent electrophysiological effect of MIDD0301 on CD4 + T lymphocytes isolated from ova s/c mouse spleen using automated patch clamp ( Figure 5 ). MIDD0301 potentiated a current response in CD4 + T cells at very low concentrations in the presence of 600 nM GABA, exhibiting a fast on-rate and rapid current decrease during the washout phase ( Figure 5, A) . The current change for MIDD0301 saturated at a concentration of 100 nM.
The data showed an EC50 of 17 nM for MIDD0301 and maximal potentiation of 512%. Patch clamp measurements with cells transfected with various GABAAR subunits indicated that MIDD0301 is activating GABAARs strongly among the alpha subtypes tested.
MIDD0301 has anti-inflammatory properties in the lung. Chronic airway inflammation is a
hallmark feature of asthma and can be measured by quantification of immune cell subtypes in the bronchoalveolar lavage fluid (BALF). We analyzed BALF from vehicle and MIDD0301 treated mice by flow cytometry using differential counts for eosinophils, macrophages, and CD4 + T cells, using Siglec F, 33 F4/80, and CD4 antibodies, respectively. Total inflammatory cells in BALF were quantified with anti-CD45. The CD45 marker is also referred to as the leukocyte common factor, which is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. 34 The results are depicted in Figure 6 . Data represent mean ± SEM from 10 mice in each group. One way ANOVA was used to calculate significance indicated as *, **, and *** for p < 0.05, p < 0.01, and p < 0.001 compared to vehicle treated ova s/c mice. The gated positive events are depicted in the Supporting Information.
We observed significant suppression of total inflammatory cells in BALF following 5 day oral administration with MIDD0301 at 100 mg/kg (Figure 6, A) . Salmeterol at 1 mg/kg p.o. did not significantly change the leukocyte numbers. Efficacy of oral MIDD0301 treatment was also observed for the BALF Siglec F + cell population that include eosinophils/alveolar macrophages 35 and F4/80 + cells that represent the murine macrophage population, though, only the 100 mg/kg dosage reduced their numbers significantly ( Figure 6 , C and D). In line with the sensitivity of CD4 + T cells toward MIDD0301 determined by patch clamp, 20, 50 and 100 mg/kg oral MIDD0301 treatments significantly reduced the number of BALF CD4 + T cells (Figure 6, B) . Although salmeterol reduced BALF CD4 + T cells (Figure 4 B) , there was no significant effect observed for macrophage and eosinophil BALF populations (Figures 4, C and D) .
Effects of MIDD0301 on the mouse lung. Lung inflammation is characterized by infiltration of
leukocytes and proliferation of airway smooth muscle cells. 36 To visualize this effect in the mouse lung, a thymidine analogue EdU was i.p. injected into vehicle and MIDD0301 (100 mg/kg) treated ova s/c mice and control mice, allowing its incorporation into DNA during S phase of DNA replication. Mice were euthanized after four hours and lungs slices prepared following a standard histology protocol. The EdU labelled DNA was made visible via its conjugation with an Alexa Fluor® 488 azide using a copper catalyzed "Click" reaction. 37 The nuclei of all cells were counterstained with Hoechst 33342, and superimposed and individual images presented in Figure   7 . EdU visualization of lung sections from control mice (non-asthmatic) revealed no cell staining except for faint non-specific background (Figure 7, column 1 and row 1) . In contrast, lung sections from vehicle-treated ova s/c mice showed intensive staining in the alveolar region (Figure 7 , column 1 and row 2). Cell layers of blood vessels (lamina and smooth muscle cells) and bronchiole (mucosa and smooth muscle cells) were not stained. Alveolar cells (pneumocytes) have not been shown to proliferate quickly in the asthmatic lung, thus infiltrating alveolar leukocytes such as eosinophils, alveolar macrophages or monocytes were probably visualized. 38 Importantly, lungs sections from MIDD0301 treated ova s/c mice (Figure 7 , column 1 and row 3) showed reduced cell staining in comparison to vehicle-treated ova s/c mice. Thus, the reduction of inflammatory cells observed in the BALF of MIDD0301 treated animals ( Figure 6, A) is consistent with the reduction of alveolar inflammatory cells visualized by EdU.
Mucous metaplasia is unchanged for MIDD0301 treated asthmatic mice. Marked mucus accumulation is a key pathological feature of asthma resulting from mucus cell metaplasia (change in epithelial cell phenotype) and goblet cell hyperplasia (increase in goblet cell number). These histologic changes in the asthmatic lung can be visualized by staining sections with periodic acid fluorescent Schiff's stain (Figure 8 ). The stained lung sections revealed significant increases in mucous metaplasia in ova s/c mice compared to control mice (Figure 8, A and B ). MIDD0301 at 20, 50 and 100 mg/kg b.i.d. for 5 days did not produce a significant change in mucous production in the airways compared to ova s/c mice. Similarly, a 5 day b.i.d treatment with salmeterol at 1 mg/kg showed no effect on mucous levels in the airways.
Cytokine expression in mouse lung homogenate is significantly reduced by MIDD0301.
Cytokines play critical functions and serve pleiotropic roles in asthma; hence concentrations of mouse TH1 (IL-2, IFN- and TNFα), TH2 (IL-4, IL-6 and IL-10), and TH17 (IL-17A) cytokines were quantified in lung homogenates using flow cytometry (Figure 9 ). 39 Figures   6C, 6D, 6E and 6C ). Cytokine levels that were significantly increased in the lung of ova s/c mice in comparison to the control mice, were in turn significantly reduced with the treatment of MIDD0301, except for IL-10. The cytokine concentrations that did not change between the control and ova s/c mice were not altered significantly by MIDD0301 treatments.
DISCUSSION
Among the various alpha GABAAR subunits, only α4 and α5 subunit containing GABAAR are expressed in airway smooth muscle. 18 Immune cells also express receptors containing these two alpha GABAAR subunits in addition to α2 and α3. 13 Thus, the presence of an overlapping subset of discrete GABAARs comprising these alpha subunits enables a novel drug design strategy to target two hallmarks of asthma: airway smooth muscle constriction and lung inflammation. To prove this rationale, prototype GABAAR ligands possessing α4β3γ2 and the α5β3γ2 efficacy were shown to alleviate both of these asthma symptoms in vitro and in vivo. 13, 14 Historically, GABAAR ligands based on the benzodiazepine scaffold have been developed to treat various CNS disorders such as anxiety and seizures. A critical innovation of MIDD0301, and earlier GABAAR ligands developed for asthma, is their altered chemical structure that restricts brain exposure but facilitates pharmacological activity to readily permeable lung tissues. Pharmacokinetic studies have confirmed negligible concentrations of MIDD0301 in the brain, which is protected by tight junctions between endothelial cells creating the blood brain barrier. The predicted logBB of -0.14 for MIDD0301, based on its total polar surface area (70.3 A 2 ) and logP (4.2), is consistent with this in vivo observation. 40 In addition, MIDD0301 caused no sensorimotor impairment in rotarod studies, as would be observed if CNS adverse effects were present. Furthermore, this study also showed that MIDD0301 did not diminish skeletal muscle coordination necessary for the animal to stay balanced on the rotating rod. This finding was observed for midazolam, which has been shown to block inactivated Na channels in skeletal muscle fibers. 41 Importantly, MIDD0301 has been shown to relax airway smooth muscle using ex-vivo substance P mediated pre-contracted guinea pig tracheal rings. Treatment with 25 μM MIDD0301 was sufficient to partially relax muscle constriction within 15 minutes. Earlier experiments with an analog of MIDD0301 have shown that the actual concentration of compound in the trachea is only 10% of the organ bath concentration due to limited passive diffusion; 13 Another critical feature of asthma is persistent goblet cell hyperplasia, mucus cell metaplasia, and mucus hypersecretion. 42 Mucus hypersecretion from hyperplastic goblet cells causes mucus plugging, particularly in the peripheral airways and is a major pathologic finding in asthma mediated deaths. 43, 44 Ovalbumin and nicotine exposure have shown to induce mucus secretion and increased expression of glutamic acid decarboxylase (GAD) and GABAAR subunits in lung epithelia cells. 21, [45] [46] [47] In these studies, bicuculline, a GABAAR antagonist that also blocks small-conductance calcium-activated potassium channels, 48 has been shown to reduce GABAinduced transmembrane current and mucin 5A expression in lung epithelia cells, as well as mucus secretion and AHR. The administration of imidazobenzodiazepine GABAAR modulators, however, did not alter the mucus production in the lung of ova s/c mice at 100 mg/kg. 12, 13 Similar results were obtained with MIDD0301 when administrated at 20, 50 or 100 mg/kg b.i.d. for 5 days.
A major pathological feature of persistent asthma is chronic allergic inflammation leading to airway eosinophilia. 49 We demonstrated a significant reduction for BALF eosinophil numbers in ova s/c mice following MIDD0301 treatment with 100 mg/kg twice daily for 5 days. In asthma, airway macrophages are one of the major cell types involved in the chronic inflammatory process and can be divided into three classes: bronchial macrophages (BMs), alveolar macrophages (AMs), and interstitial macrophages (IMs). 50 MIDD0301 at 100 mg/kg b.i.d. for 5 days reduced the number of macrophages in the BALF of ova s/c mice. Cell staining with EdU confirmed the reduction of cells the alveoli region of the lung, which might be recruited eosinophils, alveolar macrophages or monocytes, because resident alveolar macrophage proliferate very slowly or not at all. 51 Further studies will be conducted to confirm this hypothesis.
In contrast to compound 2, inflammation is reduced by MIDD0301 by direct interaction with CD4 + T cells as demonstrated by modulation of its transmembrane current in the presence of GABA. We hypothesize that this effect is mediated by the ability of MIDD0301 to activate the α2 subunit containing GABAAR, which has been identified on CD4 + T cells. 52 In vivo, airway CD4 + T cell numbers were significantly reduced in ova s/c mice following treatment with 20 mg/kg MIDD0301 b.i.d. for 5 days. In asthma, CD4 + T cells produce several TH2 interleukins such as IL-4, IL-5, and IL-13. 53 As expected, IL-4 levels in lung homogenates were reduced with the treatment of MIDD0301 in comparison to vehicle-treated ova s/c mice. IL-4 is a key cytokine in the development of allergic inflammation and major mediator of isotype switching and secretion of IgE, which in turn promotes eosinophil transmigration across endothelium, mucus secretion, and differentiation of TH2 lymphocytes leading to cytokine release. 54 Activated CD4 + T cells also produce IL-17, which mediates multiple aspects of asthma pathogenesis and has been found in extremely high levels in sputum and bronchial biopsies of patients with severe asthma. 55 Importantly, we demonstrated that MIDD0301 treatment significantly reduced IL-17A levels in lung homogenates of ova s/c mice. Low IL-17 levels might be one reason for decreased lung TNFα levels observed for MIDD0301 treated ova s/c mice due to the fact that IL-17 has been shown to stimulate TNF-α expression by macrophages. 56 The lower number of macrophages found in BALF of MIDD0301 treated ova s/c mice might contribute to the reduction of TNF-α. Low TNF-α levels are important therapeutically, because emerging evidence suggests that this pro-inflammatory cytokine plays an important role in severe refractory disease and in many aspects of the airway pathology of asthma. 57 The modulation of other cytokines such as IFN-γ, IL-6, and IL-2 is unclear because the ova s/c phenotype did not demonstrate levels significantly different from control mice. Importantly, the anti-inflammatory cytokine IL-10 expression in the lung was not significantly altered by MIDD0301 treatment.
In conclusion, following earlier development of α4β3γ2 and the α5β3γ2 selective GABAAR ligands to treat asthma, we now report a more potent, orally available asthma drug candidate MIDD0301. This compound has significantly improved anti-inflammatory properties in the lung in addition to its ability to rapidly relax constricted airway smooth muscle at low concentrations.
